Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 20, 2025Immunological MedicineOpen Access

Successful treatment of tofacitinib-refractory scleritis associated with multiple systemic inflammatory diseases using upadacitinib

View Full Paper
Ask AI
Bookmark
Share

Authors

KYKodai YugeNYNobuyo YawataKAKenichiro Asahara

Discussion

Loading...

Member takes

Overview

Case report demonstrates improved inflammation control in systemic inflammatory diseases, suggesting upadacitinib's potential efficacy.

Key Points

  • To analyze the effectiveness of upadacitinib in treating refractory scleritis associated with systemic inflammatory diseases.
  • Case report of a patient with scleritis refractory to conventional therapies and tofacitinib.
  • Assessment of inflammatory conditions including rheumatoid arthritis and ulcerative colitis.
  • Monitoring the response to treatment upon switching from tofacitinib to upadacitinib.
  • Scleritis initially treated was refractory to tofacitinib but showed renewed remission with upadacitinib.
  • Rheumatoid arthritis and ulcerative colitis were controlled with tumor necrosis factor inhibitors but scleritis remained active.
  • The transition to a selective JAK1 inhibitor was successful in managing ocular inflammation.

Cite This Study

Yuge et al. (2025) studied this question.

synapsesocial.com/papers/6924f084c0ce034ddc35039bhttps://doi.org/10.1080/25785826.2025.2588918
View Full Paper
Ask AI
Bookmark
Share